Agios officer Sarah Gheuens plans $296K share sale
The notice also lists three earlier common-share sales by Sarah Gheuens, dated August 4, October 21 and October 22, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Agios Pharmaceuticals, Inc. officer Sarah Gheuens reported a planned sale of 7,866 common shares, with an approximate sale date of October 26, 2026, and an aggregate market value of $296,467.97. Morgan Stanley Smith Barney LLC is listed as broker, and NASDAQ as the exchange. The shares are listed as acquired from the issuer through a stock option exercise, with cash payment on October 26, 2026. Earlier sales listed for Gheuens were 500 shares on October 22, 2026 ($18,760.00), 1,489 shares on October 21, 2026 ($55,881.28), and 30,000 shares on August 4, 2026 ($914,283.00).
Key Figures
Key Terms
Rule 144 regulatory
Stock Option Exercise financial
Securities To Be Sold financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What earlier AGIO stock sales did Sarah Gheuens report?
AI-generated analysis. How Rhea-AI works. Not financial advice.